Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Sex differences in distribution of cannabinoid receptors (CB1 and CB2), S100A6 and CacyBP/SIP in human ageing hearts.

Piotrowska Ż, Niezgoda M, Łebkowski W, Filipek A, Domian N, Kasacka I.

Biol Sex Differ. 2018 Nov 27;9(1):50. doi: 10.1186/s13293-018-0209-3.

2.

Comparative evaluation of CacyBP/SIP protein, β-catenin, and immunoproteasome subunit LMP7 in the heart of rats with hypertension of different etiology.

Kasacka I, Piotrowska Ż, Weresa J, Filipek A.

Exp Biol Med (Maywood). 2018 Nov 24:1535370218815435. doi: 10.1177/1535370218815435. [Epub ahead of print]

PMID:
30472885
3.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.

Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00299. Epub 2018 Jul 24.

4.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.

Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV.

Ann Oncol. 2018 Oct 1;29(10):2092-2097. doi: 10.1093/annonc/mdy336.

PMID:
30351341
5.

Comparative evaluation of cannabinoid receptors, apelin and S100A6 protein in the heart of women of different age groups.

Kasacka I, Piotrowska Ż, Filipek A, Lebkowski W.

BMC Cardiovasc Disord. 2018 Oct 4;18(1):190. doi: 10.1186/s12872-018-0923-0.

6.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV.

Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.

PMID:
30257958
7.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN.

Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25.

PMID:
30254092
8.

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

Piotrowska Z, Fintelmann FJ, Sequist LV, Jahagirdar B.

J Thorac Oncol. 2018 Oct;13(10):e204-e206. doi: 10.1016/j.jtho.2018.05.017. No abstract available.

PMID:
30244855
9.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB.

Clin Cancer Res. 2018 Aug 28. doi: 10.1158/1078-0432.CCR-18-1541. [Epub ahead of print]

PMID:
30154228
10.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00263. Epub 2018 Jul 16.

11.

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

Piotrowska Z, Gainor JF.

J Clin Oncol. 2018 Aug 1;36(22):2241-2243. doi: 10.1200/JCO.2018.79.3059. Epub 2018 Jun 4. No abstract available.

PMID:
29864378
12.

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.

Khandekar MJ, Piotrowska Z, Willers H, Sequist LV.

Oncologist. 2018 Sep;23(9):1054-1062. doi: 10.1634/theoncologist.2017-0557. Epub 2018 Apr 27. Review.

PMID:
29703765
13.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.

14.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst MJ, Engelman JA, Benes CH.

Cell Rep. 2017 Dec 12;21(11):3298-3309. doi: 10.1016/j.celrep.2017.11.051.

15.

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.

Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, Bernstein B, Ebi H, Engelman JA, Faber AC.

Clin Cancer Res. 2018 Jan 1;24(1):197-208. doi: 10.1158/1078-0432.CCR-17-1577. Epub 2017 Oct 19.

PMID:
29051323
16.

The Role of Liquid Biopsies in Lung Cancer Screening.

Dagogo-Jack I, Sequist LV, Piotrowska Z.

Semin Roentgenol. 2017 Jul;52(3):185-187. doi: 10.1053/j.ro.2017.06.001. Epub 2017 Jun 3. Review. No abstract available.

PMID:
28734402
17.

Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.

Farago AF, Piotrowska Z, Sequist LV.

J Clin Oncol. 2017 Sep 10;35(26):2987-2988. doi: 10.1200/JCO.2017.73.5696. Epub 2017 Jul 10. No abstract available.

PMID:
28692381
18.

Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.

Piotrowska Z, Sequist LV.

J Thorac Oncol. 2017 Mar;12(3):419-421. doi: 10.1016/j.jtho.2017.01.018. No abstract available.

19.

Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension.

Piotrowska Ż, Janiuk I, Lewandowska A, Kasacka I.

J Biol Regul Homeost Agents. 2016 Oct-Dec;30(4):1073-1078.

PMID:
28078856
20.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Nov 14;7:13513. doi: 10.1038/ncomms13513. No abstract available.

21.

Renovascular hypertensive decrease immunoreactivity of cells containing chromogranin A and pancreastatin in the pancreas of rats.

Piotrowska Ż, Janiuk I, Lewandowska A, Kasacka I.

Histol Histopathol. 2017 Jan;32(1):69-75. doi: 10.14670/HH-11-771. Epub 2016 Apr 25.

PMID:
27109936
22.

End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.

Bauman JR, Piotrowska Z, Muzikansky A, Gallagher E, Scribner E, Temel B, Sequist LV, Heist RS, Temel JS.

J Palliat Med. 2016 Dec;19(12):1316-1319. Epub 2016 Sep 14.

PMID:
27626514
23.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Jun 10;7:11815. doi: 10.1038/ncomms11815. Erratum in: Nat Commun. 2016 Nov 14;7:13513.

24.

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M.

Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.

25.

Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.

Piotrowska Z, Sequist LV.

JAMA Oncol. 2016 Jul 1;2(7):948-54. doi: 10.1001/jamaoncol.2016.0333. Review.

PMID:
27196961
26.

Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.

Piotrowska Z, Drapkin B, Engelman JA, Nagy RJ, Lanman RB, Sequist LV.

J Thorac Oncol. 2016 Aug;11(8):e95-e97. doi: 10.1016/j.jtho.2016.03.020. Epub 2016 Apr 12. No abstract available.

27.

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA.

Nat Med. 2016 Mar;22(3):262-9. doi: 10.1038/nm.4040. Epub 2016 Feb 1.

28.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT, Engelman JA.

JAMA Oncol. 2016 Apr;2(4):541-3. doi: 10.1001/jamaoncol.2015.5009. No abstract available.

PMID:
26720284
29.

Influence of doxazosin on biosynthesis of S100A6 and atrial natriuretic factor peptides in the heart of spontaneously hypertensive rats.

Kasacka I, Piotrowska Ż, Filipek A, Majewski M.

Exp Biol Med (Maywood). 2016 Feb;241(4):375-81. doi: 10.1177/1535370215611972. Epub 2015 Oct 28.

30.

Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?

Piotrowska Z, Sequist LV.

Oncologist. 2015 Nov;20(11):1230-2. doi: 10.1634/theoncologist.2015-0370. Epub 2015 Oct 23. No abstract available.

31.

Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.

Piotrowska Z, Sequist LV.

Cancer J. 2015 Sep-Oct;21(5):371-7. doi: 10.1097/PPO.0000000000000147. Review.

PMID:
26389761
32.

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy.

Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, Sequist LV.

J Thorac Oncol. 2015 Nov;10(11):1601-7. doi: 10.1097/JTO.0000000000000648.

33.

Influence of renovascular hypertension on the distribution of vasoactive intestinal peptide in the stomach and heart of rats.

Kasacka I, Piotrowska Ż, Janiuk I.

Exp Biol Med (Maywood). 2015 Nov;240(11):1402-7. doi: 10.1177/1535370215587533. Epub 2015 May 19. Erratum in: Exp Biol Med (Maywood). 2016 May;241(9):1014.

34.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA.

Clin Cancer Res. 2015 Sep 1;21(17):3924-33. doi: 10.1158/1078-0432.CCR-15-0560. Epub 2015 May 11.

35.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, Parks MK, DiCecca RH, Dias-Santagata D, Iafrate AJ, Shaw AT, Allen AR, Engelman JA, Sequist LV.

Cancer Discov. 2015 Jul;5(7):713-22. doi: 10.1158/2159-8290.CD-15-0399. Epub 2015 May 1.

36.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR.

N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.

PMID:
25923550
37.

Alterations of rat stomach endocrine cells under renovascular hypertension.

Kasacka I, Piotrowska Z, Lewandowska A.

Adv Med Sci. 2014 Sep;59(2):190-5. doi: 10.1016/j.advms.2014.01.004. Epub 2014 Jun 9.

PMID:
25323756
38.

Evaluation of CART-, glucagon-, and insulin-immunoreactive cells in the pancreas of an experimental rat model of unilateral renal artery stenosis.

Kasacka I, Janiuk I, Piotrowska Z.

Histol Histopathol. 2015 Apr;30(4):445-52. doi: 10.14670/HH-30.445. Epub 2014 Sep 17.

PMID:
25229552
39.

Quantitative and qualitative evaluation of CART-containing cells in adrenal glands of male rats with hypertension.

Kasacka I, Piotrowska Ż, Knaś M, Lewandowska A.

Biotech Histochem. 2014 Oct;89(7):497-504. doi: 10.3109/10520295.2014.902503. Epub 2014 Aug 25.

PMID:
25151991
40.

Dynamics of cocaine- and amphetamine-regulated transcript containing cell changes in the adrenal glands of two kidney, one clip rats.

Kasacka I, Piotrowska Z, Janiuk I, Zbucki R.

Exp Biol Med (Maywood). 2014 Oct;239(10):1292-9. doi: 10.1177/1535370214538593. Epub 2014 Jun 17.

PMID:
24939825
41.

Cocaine- and amphetamine-regulated transcript : identification and distribution in human gastrointestinal tract.

Kasacka I, Piotrowska Z, Car H, Janiuk I, Lebkowski W.

J Biol Regul Homeost Agents. 2012 Jul-Sep;26(3):419-28.

PMID:
23034261
42.

Evaluation of density and distribution of CART-immunoreactive structures in gastrointestinal tract of hypertensive rats.

Kasacka I, Piotrowska Z.

Biofactors. 2012 Nov-Dec;38(6):407-15. doi: 10.1002/biof.1037. Epub 2012 Aug 8. Erratum in: Biofactors. 2014 Mar-Apr;40(2):275.

PMID:
22887004
43.

Is reproduction costly? No increase of oxidative damage in breeding bank voles.

Ołdakowski Ł, Piotrowska Z, Chrzaácik KM, Sadowska ET, Koteja P, Taylor JR.

J Exp Biol. 2012 Jun 1;215(Pt 11):1799-805. doi: 10.1242/jeb.068452.

44.

Rhinoviruses are a major cause of wheezing and hospitalization in children less than 2 years of age.

Piotrowska Z, Vázquez M, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS.

Pediatr Infect Dis J. 2009 Jan;28(1):25-9. doi: 10.1097/INF.0b013e3181861da0.

45.

Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.

Planck M, Ericson K, Piotrowska Z, Halvarsson B, Rambech E, Nilbert M.

Cancer. 2003 Mar 15;97(6):1551-7.

46.

Defective mismatch-repair in patients with multiple primary tumours including colorectal cancer.

Ericson K, Halvarsson B, Nagel J, Rambech E, Planck M, Piotrowska Z, Olsson H, Nilbert M.

Eur J Cancer. 2003 Jan;39(2):240-8.

PMID:
12509957
47.

[Cases of poisoning with mushrooms].

Piotrowska Z, Wagner A.

Wiad Lek. 1968 Sep 1;21(15):1335-8. Polish. No abstract available.

PMID:
5697946

Supplemental Content

Loading ...
Support Center